Drugs / BASIC FIBROBLAST GROWTH FACTOR (HUMAN)

Trials 2

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT06448039 Jun 2024 → May 2026 overdue chronic otitis media D. Bradley Welling, MD, PhD Active not recruiting No outcome recorded
Phase not applicable1 trial
— NCT04234321 Aug 2020 → Jun 2022 — Second Affiliated Hospital, School of Medicine, Zhejiang University Unknown No outcome recorded

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as BASIC FIBROBLAST GROWTH FACTOR (HUMAN) ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as basic fibroblast growth factor ClinicalTrials.gov intervention name — accepted as the source's own label NCT04234321 ↗
Known as Bio-fd&c bfgf ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as Cg-bfgf ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as Fibroblast Growth Factor 2 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06448039 ↗
Known as Heparin-binding growth factor 2 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as Human oligopeptide-3 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as Recombinant bfgf (143-288) ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as Rh-polypeptide-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Known as Sh-polypeptide-1 ChEMBL registry synonym — accepted as the source's own label CHEMBL6068603 ↗
Modality Protein / enzyme biologic — CHEMBL6068603 ↗
Route Topical “topical application of FGF-2” NCT06448039 ↗